Lilly/BI’s Jardiance Is First Diabetes Drug To Show A CV Benefit – Now What?
This article was originally published in The Pink Sheet Daily
The SGLT2 inhibitor demonstrated superiority in a 7,000-patient cardiovascular outcomes trial. The implications for the class of drugs – and the broader diabetes treatment market – could be substantial.
Register for our free email digests: